Develops antibody therapies for chronic urticaria (hives), mast cell disorders and cancer.
Develops antibody therapies for chronic urticaria (hives), mast cell disorders and cancer.
Has no product sales; trial costs are paid from money raised from investors. Barzolvolimab is in late-stage trials for chronic hives and related skin disorders, so the next steps are trial results and, if approved, building a sales force or finding a partner to sell it.
Moat: none (IP / patents). Clinical-stage biotech with a differentiated mast-cell-targeting antibody but no approved products yet.
Headquarters: Hampton, New Jersey, US · Founded: 1983 · Employees: 198
Size Celldex Therapeutics (CLDX) is a United States Health Care company (Biotechnology) with a market value of $2.16B, the 1724th largest of 3,085 United States companies the cockpit tracks. Shares closed at $27.55 on 18 Nov 2026.
Performance Over six months the shares fell 10.8%, against -11.6% for the median peer and -2.2% for the United States market (cap-weighted) — 10th highest of 20 in its peer set.
Growth Revenue fell 93.9% over the last twelve months (peer median +4.1%); the operating margin is -211,684.8% (peer median -15.4%).
Valuation It trades at 9,677.0× enterprise value to sales against a peer median of 9.4× (most expensive of 15).
Next results Next results expected around 1 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $158,000 | $1.54M | $7.02M | $6.88M | $2.36M |
| Revenue growth | — | -78% | +2% | +192% | — |
| Gross profit | -$3.58M | -$1.83M | $3.84M | $3.88M | $957,000 |
| EBITDA | -$331M | -$284M | -$192M | -$139M | -$106M |
| Net income | -$309M | -$259M | -$158M | -$141M | -$112M |
| Free cash flow | -$260M | -$214M | -$160M | -$109M | -$106M |
| Capital expenditure | $7.77M | $2.71M | $1.92M | $1.82M | $1.83M |
| Total debt | $9.87M | $2.34M | $3.81M | $2.54M | $4.03M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Celldex Therapeutics CLDX | $2.16B | -11% | -94% | -211,685% | 9,677.0× | n/a |
| Amgen AMGN | $240B | +34% | +9% | 36% | 7.2× | 1.6% |
| Cogent Biosciences COGT | $4.84B | -16% | n/a | n/a | n/a | n/a |
| Novartis NOVN.SW | $285B | +11% | -4% | 30% | 6.2× | 1.6% |
| Sanofi SAN.PA | $114B | +13% | +15% | 27% | 2.6× | -4.8% |
| Roche RO.SW | $381B | +21% | -1% | 31% | 5.7× | 1.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CLDX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.1% | -4.9% | 9th lowest of 21 |
| 6-month return | -10.8% | -11.6% | 10th highest of 20 |
| Distance from 52-week high | -39.0% | -34.1% | 9th lowest of 21 |
| Revenue growth (TTM) | -93.9% | +4.1% | 3rd lowest of 17 |
| Operating margin | -211,684.8% | -15.4% | lowest of 15 |
| EV / Sales | 9,677.0× | 9.4× | most expensive of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Celldex Therapeutics CLDX | United States | $2.16B | -11% | -94% | -211,685% | 9,677.0× | n/a | n/a |
| Zealand Pharma A/S ZEAL.CO | Denmark | $2.16B | -30% | -50% | 46% | 0.4× | n/a | n/a |
| Beam Therapeutics BEAM | United States | $2.17B | -22% | +163% | -268% | 9.4× | n/a | n/a |
| Palvella Therapeutics PVLA | United States | $2.14B | +27% | -100% | n/a | n/a | n/a | n/a |
| BGI Genomics 300676.SZ | China | $2.13B | -15% | 0% | -14% | 3.2× | n/a | n/a |
| Alamar Biosciences ALMR | United States | $2.12B | +51% | +195% | -42% | 26.1× | n/a | n/a |
| Pharvaris PHVS | United States | $2.21B | +7% | n/a | n/a | n/a | n/a | n/a |
| SKBS 302440.KS | South Korea | $2.25B | -12% | +11% | -23% | 4.3× | n/a | n/a |
| Vimian VIMIAN.ST | Sweden | $2.26B | +51% | +8% | 19% | 5.0× | 13.4% | +44.5% |
| Evopoint Biosciences 688837.SS | China | $2.08B | n/a | n/a | n/a | 53.6× | n/a | n/a |
| Lakefront Biotherapeutics LKFT.AS | Netherlands | $2.26B | +31% | +223% | 64% | n/a | n/a | n/a |
| Arcus Biosciences RCUS | United States | $2.27B | -34% | -58% | -475% | 17.6× | n/a | n/a |
| Aurinia Pharmaceuticals AUPH | United States | $2.03B | -5% | +21% | 45% | 5.0× | 3.5% | +41.4% |
| Hebei Changshan Biochemical Pharmaceutical 300255.SZ | China | $2.33B | -59% | 0% | -25% | 19.4× | n/a | n/a |
| Immunome IMNM | United States | $1.98B | -22% | -100% | n/a | n/a | n/a | n/a |
| Trevi Therapeutics TRVI | United States | $1.93B | -3% | n/a | n/a | n/a | n/a | n/a |
| Maravai Lifesciences MRVI | United States | $1.92B | +101% | +11% | -17% | 10.2× | n/a | n/a |
| Sinocelltech 688520.SS | China | $1.90B | -35% | -40% | -75% | 13.6× | n/a | n/a |
| Walvax Biotechnology 300142.SZ | China | $2.48B | -26% | -23% | 5% | 9.4× | 29.5% | -3.8% |
| BioCryst Pharmaceuticals BCRX | United States | $1.88B | -16% | +60% | 42% | 2.4× | -11.0% | +117.9% |
| Replimune REPL | United States | $1.88B | +321% | n/a | n/a | n/a | n/a | n/a |